Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab
Annette Langer-Gould, Jessica B Smith, Edlin G Gonzales, Rhina D Castillo, Judith Garza Figueroa, Anusha Ramanathan, Bonnie H Li, Michael K Gould, Annette Langer-Gould, Jessica B Smith, Edlin G Gonzales, Rhina D Castillo, Judith Garza Figueroa, Anusha Ramanathan, Bonnie H Li, Michael K Gould
Abstract
Objective: To examine outcomes among patients who were treated with the targeted anti-cytokine agents, anakinra or tocilizumab, for COVID-19 -related cytokine storm (COVID19-CS).
Methods: We conducted a retrospective cohort study of all SARS-coV2-RNA-positive patients treated with tocilizumab or anakinra in Kaiser Permanente Southern California. Local experts developed and implemented criteria to define COVID19-CS. All variables were extracted from electronic health records.
Results: At tocilizumab initiation (n = 52), 50 (96.2%) were intubated, and only seven (13.5%) received concomitant corticosteroids. At anakinra initiation (n = 41), 23 (56.1%) were intubated, and all received concomitant corticosteroids. Fewer anakinra-treated patients died (n = 9, 22%) and more were extubated/never intubated (n = 26, 63.4%) compared to tocilizumab-treated patients (n = 24, 46.2% dead, n = 22, 42.3% extubated/never intubated). Patients who died had more severe sepsis and respiratory failure and met COVID-CS laboratory criteria longer (median = 3 days) compared to those extubated/never intubated (median = 1 day). After accounting for differences in disease severity at treatment initiation, this apparent superiority of anakinra over tocilizumab was no longer statistically significant (propensity score-adjusted hazards ratio 0.46, 95% confidence interval 0.18-1.20).
Conclusions: Prompt identification and treatment of COVID19-CS before intubation may be more important than the specific type of anti-inflammatory treatment. Randomized controlled trials of targeted anti-cytokine treatments and corticosteroids should report the duration of cytokine storm in addition to clinical severity at randomization.
Keywords: Anakinra; COVID-19; Corticosteroids; Cytokine storm; Tocilizumab.
Copyright © 2020 Southern California Permanente Medical Group. Published by Elsevier Ltd.. All rights reserved.
Figures
References
- Barnes B.J., Adrover J.M., Baxter-Stoltzfus A., Borczuk A., Cools-Lartigue J., Crawford J.M. Targeting potential drivers of COVID-19: Neutrophil extracellular traps. J Exp Med. 2020;217(6) doi: 10.1084/jem.20200652.
- Cavalli G., De Luca G., Campochiaro C., Della-Torre E., Ripa M., Canetti D., Dagna L. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020;2(6):e325–e331. doi: 10.1016/S2665-9913(20)30127-2.
- Halyabar O., Chang M.H., Schoettler M.L., Schwartz M.A., Baris E.H., Benson L.A., Henderson L.A. Calm in the midst of cytokine storm: a collaborative approach to the diagnosis and treatment of hemophagocytic lymphohistiocytosis and macrophage activation syndrome. Pediatr Rheumatol Online J. 2019;17(1):7. doi: 10.1186/s12969-019-0309-6.
- Jordan M.B., Allen C.E., Greenberg J., Henry M., Hermiston M.L., Kumar A. Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO. Pediatr Blood Cancer. 2019;66(11):e27929. doi: 10.1002/pbc.27929.
- Koebnick C., Langer-Gould A.M., Gould M.K., Chao C.R., Iyer R.L., Smith N., Jacobsen S.J. Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data. Perm J. 2012;16(3):37–41. doi: 10.7812/tpp/12-031.
- Lee D.W., Gardner R., Porter D.L., Louis C.U., Ahmed N., Jensen M., Mackall C.L. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188–195. doi: 10.1182/blood-2014-05-552729.
- Mehta P., McAuley D.F., Brown M., Sanchez E., Tattersall R.S., Manson J.J. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–1034. doi: 10.1016/S0140-6736(20)30628-0.
- Toniati P., Piva S., Cattalini M., Garrafa E., Regola F., Castelli F., Latronico N. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Autoimmun Rev. 2020;19(7):102568. doi: 10.1016/j.autrev.2020.102568.
- University of Oxford . 2020. RECOVERY: Randomised Evaluation of COVID-19 Therapy. Retrieved from (accessed 18 June 2020)
- Xu X., Han M., Li T., Sun W., Wang D., Fu B., Wei H. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020;117(20):10970–10975. doi: 10.1073/pnas.2005615117.
- Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. doi: 10.1016/S0140-6736(20)30566-3.
Source: PubMed